Compass Therapeutics (CMPX) Common Equity (2023 - 2025)
Historic Common Equity for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $209.6 million.
- Compass Therapeutics' Common Equity rose 5145.67% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 5145.67%. This contributed to the annual value of $125.2 million for FY2024, which is 1568.96% down from last year.
- Latest data reveals that Compass Therapeutics reported Common Equity of $209.6 million as of Q3 2025, which was up 5145.67% from $93.2 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Common Equity registered a high of $209.6 million during Q3 2025, and its lowest value of $93.2 million during Q2 2025.
- Moreover, its 3-year median value for Common Equity was $148.5 million (2023), whereas its average is $148.4 million.
- Over the last 5 years, Compass Therapeutics' Common Equity had its largest YoY gain of 5145.67% in 2025, and its largest YoY loss of 3620.5% in 2025.
- Compass Therapeutics' Common Equity (Quarter) stood at $148.5 million in 2023, then decreased by 15.69% to $125.2 million in 2024, then skyrocketed by 67.38% to $209.6 million in 2025.
- Its Common Equity stands at $209.6 million for Q3 2025, versus $93.2 million for Q2 2025 and $110.3 million for Q1 2025.